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Introduction
\body Major depressive disorder (MDD) is the leading cause of disability worldwide (1, 2) and is increasingly common with a lifetime prevalence in the United States of more than 20% (3) . Combating this endemic disease will require improvements in prophylaxis and treatments; however, the development of both is limited in part by insufficient understanding of the neurological changes associated with disease remission.
Investigating the network-level changes associated with remission from MDD has been particularly challenging due to disease heterogeneity of MDD (7, 8) , as well as antidepressant medications requiring weeks-to-months to induce remission (4) with limited efficacy (5, 6) . Conventional repetitive transcranial magnetic stimulation (rTMS) has been used to investigate functional connectivity changes that occur with remission (7) ; however, conventional rTMS also requires several weeks to induce remission with less than half of patients remitting (8) . Electroconvulsive therapy (ECT) has greater efficacy and more rapid onset of action than antidepressant medications; however, mean onset is still >2 weeks (9) , open-label remission rates occur in only 50-65% of patients (5) , and there are numerous significant off-target effects, including cognitive disturbances (10) and effects on the motor system (11) , making it difficult to determine which network changes are specific to remission from depression. Ketamine induces brief remission rapidly but only in a third of patients (12, 13) and with significant off-target effects (14, 15) . Incipient investigations of potent agonists demonstrate high rates of rapid remission (16, 17) ; yet, the off-target effects are profound (18) . We recently developed a form of repetitive transcranial magnetic stimulation (rTMS) that induces remission in 90% of individuals with severe, treatment-resistant MDD in a mean of ~3 days without off-target effects (19, 20) .
This treatment provides a new opportunity to investigate the network alterations associated with remission from MDD.
We chose to begin our investigation at the network level with a resting-state functional connectivity (FC) analysis, because neuroimaging-based approaches that assess resting-state FC have demonstrated some success in investigating neurocircuit-level dysfunction of MDD. These approaches have been used to investigate neurophysiological subtypes of MDD (21, 22) and predict treatment efficacy of rTMS (23, 24, 22, (25) (26) (27) (28) (29) (30) . Given the promise of this approach, we performed resting state FC analyses on participants before and after SAINT. For this initial investigation, we restricted our analysis to brain regions involved in emotion regulation, as these regions have well-described associations with MDD.
Several lines of evidence suggest dysfunction of emotion regulation in MDD (31) with neural correlates observed with fMRI (32, 33) . The neural basis of emotion regulation includes emotional reactivity: amygdala and striatum; explicit control of emotion -central executive network (CEN): dorsolateral prefrontal cortex (dlPFC), ventrolateral PFC (vlPFC); and implicit emotion regulation -default mode network (DMN), salience affective network (SN) and insula. For review, see Etkin et al. (34) . Specifically, dysfunction within the DMN, CEN, and SN has repeatedly been reported in individuals with MDD (35) (36) (37) (38) (39) . Numerous fMRI studies have demonstrated that individuals with MDD have altered frontal connectivity with amygdala (40) (41) (42) (43) (44) and striatum (23, (45) (46) (47) ; hyperconnectivity between DMN and amygdala (48-51) ; and alterations in insular connectivity with multiple nodes (51) (52) (53) .
Following the emotional dysregulation hypothesis of depression, stimulation of the CEN at the lDLPFC node, via rTMS (37, 54, 55) and transcranial direct current stimulation (56) , has been hypothesized to produce antidepressant effects by enhanced regulation of emotion. This is in line with Chen et al's seminal interleaved TMS/fMRI study demonstrating causal interactions between CEN and DMN, such that increased activity in CEN results in suppression of DMN (57) , and this has led others to hypothesize that improved accuracy of targeting these networks might produce better treatment efficacy (27) (28) (29) (58) (59) (60) , as only a third or less of participants remit from their depressive episode with rTMS stimulation of the lDLPFC, a CEN node (61) (62) (63) .
We hypothesized that individualized targeting and enhanced stimulation techniques could improve outcomes (20) , and we developed Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT). In our initial open-label trial of SAINT in patients with severe, treatment-resistant depression, we observed a strikingly high remission rate of 90% with a mean of ~3 days of treatment to produce remision (19) . Thus, FC changes that occur with SAINT may reflect generalized network-level changes associated with remission from depression.
Herein, we report our first investigation of the resting-state FC changes that occur in participants with MDD undergoing open-label SAINT.
Results

Depression symptoms
Nineteen participants with a diagnosis of severe MDD [Hamilton Depression Rating Scale 17-item (HAMD-17) score greater than 20, 9 males, age 50.11±14.58 (mean±SD) range 20-78 years] and a treatment history of not responding to at least 1 antidepressant medication (minimum trial duration of 6 weeks) were recruited for the study and received MRI scans before and after SAINT. Participants received a 5-day treatment course under the SAINT protocol. Stimulation location was depth-corrected (52) and chosen based on an algorithm that selected the area within the left dorsolateral prefrontal cortex (lDLPFC) with the most negative FC with sgACC (19) . Ten sessions per day of intermittent theta-burst stimulation [iTBS, 60 cycles of 10 bursts of 3 pulses at 50Hz delivered in 2-second trains with an 8-second inter-train interval] were delivered hourly at 90% resting motor threshold for 5 consecutive days for a total of 90,000 pulses. Nineteen participants had complete structural and resting-state functional MRI scans both pre-and post-SAINT.
Mean HAMD-17 significantly decreased from 26.280 (±4.909, range 20-35) at baseline to 4.722 (±4.599, range 0-16) after treatment ( t (17) =11.275, p<0.001 ). Mean MADRS significantly decreased from 33.220 (±5.208, range 27-44) at baseline to 4.833 (±5.813, range 0-19) after treatment ( t (17) =14.915, p<0.001) .
Baseline HAMD-17 and MADRS scores were highly correlated (r=0.817, p<0.001), as were the percent-change scores from baseline to post-treatment (r=0.948, p<0.001). MADRS was used as the primary clinical outcome for all FC analyses, and all results are equivalent for HAMD-17.
Functional connectivity changes
We examined FC changes that occurred with SAINT. Paired t-tests (FDR-corrected) demonstrated significant decrease in FC between lsgACC and 3 of 4 DMN nodes (lsgACC-fDMN: t (17) =2.335, q =0.036; lsgACC-mDMN: t (17) =3.027, q=0.008; lsgACC-rDMN: t (17) =2.660, q=0.017). A similar trend was found for FC between lsgACC and lDMN (t (17) =2.106, q=0.06) ( Figure 1 ). FC reductions were also observed between rDLPFC and amygdala (t (17) =2.303, q=0.036), and striatum (rDLPFC-limS: t (17) =2.354, q=0.032), between SN nodes and amygdala (AI-lCMA: t (17) =3.601, q=0.002; AI-rCMA: t (17) =3.167, q=0.006; dACC-rBLA: t (17) =2.515, q=0.023; AI-rBLA: t (17) =2.206, q=0.045), between DMN and amygdala (fDMN-rCMA: t (17) =2.491, q=0.024; fDMN-rSA: t (17) =2.520, q=0.023), between DMN and striatum (fDMN-limbic striatum: t (17) =2.281, q=0.039; rDMN-executive striatum: t (17) =2.303, q=0.037; rDMN-limbic striatum: t (17) =2.279, q=0.039), between left insula and amygdala (linsula-lCMA: t (17) =2.177, q=0.049, linsula-rBLA: t (17) =2.221, q=0.045), between amygdala and striatum (lCMA-limbic striatum: t (17) =2.515, q=0.023), and between amygdala sub-regions (lCMA-rCMA: t (17) =3.601, q=0.002; lCMA-rBLA: t (17) =2.276, q=0.024; rCMA-rSA: t (17) =2.481, q=0.040) ( Figure 1 ). Select non-significant results are also included in Figure   1 .
Functional connectivity changes associated with clinical changes
We assessed the relationship between changes (percent change from baseline) in FC and depression symptoms using standard linear regression techniques adjusted for multiple comparisons (FDR).
Changes in FC between lDLPFC and other ROIs were significantly associated with changes in MADRS
scores with better clinical outcomes correlated with greater decreases in FC between lDLPFC and lCMA (R 2 =0.210, t (17) =2.351; q=0.033) and between lDLPFC and linsula (R 2 =0.228, t (17) =2.452; q=0.026). Similarly, changes in FC between insula and amygdala were significantly associated with changes in MADRS scores with better clinical outcomes correlated with greater decreases in FC between rinsula and rBLA (R 2 =0.215, t (17) =2.377; q=0.031) ( Figure 2 ).
In contrast, smaller magnitude reductions (and larger magnitude increases) in FC between sgACC and DMN nodes were associated with better clinical outcomes. Specifically, greater depression symptom improvements were correlated with increased FC between rsgACC and lDMN (R 2 =0.225, t (17) =-2.437, q=0.027) and FC between lsgACC and mDMN (R 2 =0.219, t (17) =-2.399, q=0.029). Although the overall group mean FC decreased with SAINT (see prior section), larger magnitude percent-reductions in MADRS scores were associated with smaller reductions and larger increases in FC between sgACC and DMN. The same relationship was found for FC between linsula and rSA (R 2 =0.291, t (17) =-2.827, q=0.012) ( Figure 2 ).
Gender and age were not found to be confounders (all p's>0.05), and all significant effects remained when including gender and age as covariates in multiple-regression models (all q's<0.05).
Baseline functional connectivity association with clinical changes
We assessed the association between baseline FC and changes in MADRS scores with a similar linear regression approach. Larger improvements in MADRS scores were correlated with lower baseline FC between lDMN and frontal cortex (rVLPFC-lDMN: R 2 =0.235, t (17) =2.496; q=0.024; rDLPFC-lDMN: R 2 =0.231, t (17) =2.470; q=0.026) and between lDMN and striatum (limbic striatum-lDMN: R 2 =0.312, t (17) =2.951; q=0.009; executive striatum-lDMN: R 2 =0.306, t (17) =2.917; q=0.010) ( Figure 3 ).
Comprehensive results
Please see Supplementary Figure S1 for heat maps depicting all FC changes that were observed following SAINT. All pairwise comparisons for changes in FC following SAINT can be found in Supplementary   Table 1 . All linear regressions between change in FC and changes in MADRS are reported in Supplementary   Table 2 . All linear regressions between baseline FC and changes in MADRS are reported in Supplementary   Table 3 .
Discussion
The development of SAINT has provided us with a unique opportunity to assess the FC changes that occur during rapid remission from severe, treatment-resistant MDD. The analysis we undertook in this initial report focused on brain regions associated with emotion regulation, and we found that FC significantly decreases between several of these regions following SAINT-induced remission from MDD, with the magnitude of FC change often correlating with symptom improvement. Moreover, we found pre-treatment connectivity between several regions to be predictive of the magnitude of this improvement.
Notably, we observed a significant reduction in mean sgACC-DMN connectivity after SAINT, and this reduction was present between sgACC and 3 of 4 DMN nodes, with a nearly significant trend in the remaining node. In previous studies of depression, hyper-activity/connectivity within DMN has been considered as evidence of dysfunction of rumination and self-referential processing, and antidepressant treatment is hypothesized to normalize DMN activity and connectivity (24, 37, (64) (65) (66) . Our results support this hypothesis and raise another important question: Does the magnitude of overall suppression of DMN FC track with antidepressant treatment efficacy? Prior studies have reported significant reductions in FC between sgACC and 1 to 2 nodes of DMN (24, 37, (64) (65) (66) ; whereas, we observed significant reduction in FC in nearly all DMN nodes. Bearing in mind that SAINT induced remission in 90% of participants in 1-5 days (19) , this question deserves careful consideration in future studies.
Moreover, this hypothesis builds on some of the earliest neuroimaging studies in the field of psychiatry, which reported increased sgACC activity in patients during depressive episodes (85) . This has been hypothesized to be causally related to reductions in lDLPFC activity (86) and reinforced by observations that antidepressant treatments lead to reductions in sgACC activity (77, 79, (87) (88) (89) (90) (91) (92) . For review, see Hamani et al (2011) . Early investigators concomitantly reported observations of hypometabolism and hypoperfusion in the lDLPFC of patients with MDD (72) (73) (74) . Later investigators demonstrated that lDLPFC activity is restored with treatment of MDD (75) (76) (77) (78) (79) (80) (81) (82) , and this early data prompted investigators to begin hypothesizing a major role of top-down dysfunction in the pathophysiology of depression (83, 84) .
This led to the conception of depression as dysregulation in corticolimbic systems (Mayberg, 1997) . In recent years, this concept has continued to evolve to include neural networks and their interactions. Several groups have reported evidence that depression is associated with increased FC between sgACC and DMN (22, 23, 40, (93) (94) (95) (96) (97) , and others have shown that stimulation of lDLPFC potentiates upstream neural circuits to normalize sgACC-DMN connectivity (12, 24, (98) (99) (100) . This does not seem to be limited to individuals with depression, as rTMS of lDLPFC also has been shown to improve mood and reduce connectivity between sgACC and DMN in never-depressed participants (101) . Thus, we hypothesize that the significant reduction in FC in nearly all DMN nodes that we observed in SAINT may reflect the normalization of DMN hyper-connectivity associated depression and in part underlie its remission.
Interestingly, at the group level, FC between sgACC and DMN significantly decreased following SAINT in our cohort; however, individual changes in FC magnitude showed that participants with increased FC between sgACC and DMN actually had the greatest clinical improvement. One interpretation is that "normalization of FC between sgACC and DMN" is more complex than magnitude of FC change between 2 nodes. Alternately, disease heterogeneity may be related to changes in FC that are challenging to predict at the individual level with current approaches. Others have reported the opposite direction of association with the largest improvements in depression being associated with the largest reductions in FC between sgACC and mDMN (66) ; however, their patient cohort had comorbid post-traumatic stress disorder, which may respond differently to rTMS of the lDLPFC (67) . Further, both Philip et al (66) and our current report found an overall reduction in mean FC between sgACC and DMN in participants with improved depressive symptoms. This possible discrepancy could also be due to the limited variability in post-treatment MADRS scores in our sample. Also, we do not know how FC changed throughout the treatment course.
Those who responded the earliest generally had larger reductions in MADRS scores; thus, there could be a staged, non-monotonic change in FC whereby FC initially decreases until symptoms remit and then increases with continued treatment. A similar non-monotonic time course has been reported for psilocybin, whereby acute administration decouples sgACC from DMN (68) , but this connectivity increases from baseline in the days following treatment (16) . Thus, additional studies will be crucial to determine the validity, reliability, and meaning of this association.
Our assessment of the association between baseline FC and clinical improvements in depression scores also revealed a central role of the DMN. Greater clinical improvements were associated with lower baseline FC between DMN and DLPFC, striatum, and ventrolateral prefrontal cortex. Although FC between DLPFC and DMN predicts efficacy of ECT (69) , other studies with similar findings could not be located. Past studies that have utilized FC to predict response have found that FC between stimulation site lDLPFC and striatum predicts TMS (23, 25) , and several groups have reported that FC between stimulation site and sgACC that is more negative results in greater reductions in depressive symptoms with rTMS (28, 29, 59) . In our current study, we optimized targeting by stimulating the portion of lDLPFC with maximum anticorrelation with sgACC; thus, it is possible that this may underlie the striking reductions in depression symptoms we observed.
Finally, in contrast to antidepressant medications (30) , intact baseline connectivity between DMN and ACC was not related to outcomes following SAINT. Considering that depressive disorders may be distinguished based on intrinsic connectivity (70) , it is interesting to note that SAINT was largely effective regardless of baseline FC, which may indicate that its mechanism of action affects circuits shared between subtypes of depressive disorders.
In addition to reduced FC between sgACC and DMN, we observed several other notable changes in FC. Specifically, we found reductions in connectivity between DLPFC and amygdala, insula, and limbic striatum to be associated with clinical improvement in depression. For rDLPFC-left amygdala FC, in addition to finding reduced positive FC, we also found that greater clinical improvement was associated with larger decreases in FC. Several fMRI studies have demonstrated that individuals with MDD have altered frontal connectivity with amygdala (40) (41) (42) (43) (44) . Depressed individuals may have increased positive connectivity between rDLPFC and left amygdala (71, 72) , and individuals with depression have an impaired ability to regulate negative emotions (41) . Considering that non-depressed individuals can better suppress amygdala activity (43, 44) , our results here could represent a partial normalization of connectivity related to improved emotion regulation, i.e. baseline positive FC between rDLPFC-amygdala is pathological, a reduction in positive FC is improved, and negative FC is normalized; however, our experimental design did not include never-depressed participants, so this remains speculative. Our combined findings of changes in FC with sgACC and amygdala following DLPFC stimulation with SAINT is supported by recent work with interwoven TMS and fMRI that showed DLPFC stimulation engages these nodes (73) .
Similarly, we found that greater clinical improvements were associated with larger decreases in FC between lDLPFC and insula. Insula has a well-known role in interoception (74, 75) , and insula activity is correlated with abnormal interoception in MDD (76) . Insula metabolism has been linked to predicting antidepressant treatment response, and has thus been proposed as a depression biomarker (77) . Our results here are similar to other reports. Theta-burst rTMS stimulation of lDLPFC has been reported to reduce the magnitude of FC between lDLPFC and right insula (78) with baseline FC between these structures predicting clinical response (79) . Interestingly, individuals with subthreshold depression have lower FC between DLPFC (laterality not specified) and left insula compared to non-depressed individuals (80) . This apparent directional mismatch highlights the importance of determining the causality of mechanism using within-subject analyses prior to using these findings as biomarkers to optimize treatment efficacy.
We also observed reduced FC in rDLPFC-limbic striatum following SAINT. Increased rDLPFC-dorsal caudate connectivity has been reported to correlate with increased depression severity (81) , and FC between rDLPFC and ventral rostral putamen has been shown to decrease following depression treatment (82) .
Similarly, Furman et al found that depressed individuals have greater FC between DLPFC and dorsal caudate,
and this FC was significantly correlated with depression severity, but they did not specify laterality (45) . This association has also been reported for lDLPFC-ventral striatum FC. Avissar et al reported that improvement in depression correlated with more reduction in lDLPFC-ventral striatum FC following treatment with rTMS of lDLPFC (23) . Thus, reducing DLPFC-striatum FC may be an important route to inducing remission from depression. The combined results show consistent association between significant changes in DLPFC FC with limbic structures following SAINT, which supports the hypothesis that regulation of emotion plays a central role in MDD.
This hypothesis is further supported by our observation that following SAINT we found a significant decoupling of SN nodes, i.e. reduced FC between amygdala-insula, amygdala-dACC, amygdala-limbic striatum, and between amygdala subregions. Increased SN FC has been reported to be associated with decreased anticipated pleasure (83) and MDD (84) . Further, other groups have reported that individuals with MDD have greater FC between insula and amygdala (76, 85) and amygdala and striatum (85) . This dysfunction in SN FC may underlie the biased reactivity to negative emotions observed in individuals with MDD (84, 86) .
Some results we observed are more challenging to interpret. For example, following SAINT, FC significantly decreased between fDMN and multiple subregions of right amygdala and between multiple DMN nodes and striatum. rTMS of the lDLPFC has previously been shown to reduce FC between DMN and striatum in non-depressed individuals (87) . However, other reports suggest the opposite association for mDMN (posterior cingulate cortex and precuneus): Individuals with depression have reduced FC between amygdala and precuneus compared to non-depressed controls (88) , and connectivity between amygdala and posterior cingulate cortex is greater in less depressed individuals (89) . Our finding that FC between DMN and striatum decreased after SAINT is consistent with groups who have observed a similar change with antidepressant (90) and ECT treatment (91) . Others have reported that FC between mDMN and caudate is reduced in depressed individuals (92) , indicating this may be a compensatory mechanism; however, this is complicated by reports that reduced FC between DMN and ventral striatum is associated with impaired reward responsivity (93) . Thus, a causal association between these changes in FC with depression is difficult to infer at this time. On the other hand, the high proportion of remitters increases our confidence in mean changes in functional connectivities across the group. Follow-up controlled trials will be helpful in determining the reliability of the findings we observed here. A limitation of our neuroimaging methods is that our resolution was insufficient to explore the role of hippocampus and its sub-regions. As the hippocampus has numerous reports describing an important role in depression (94) , future studies of SAINT would benefit from assessment of FC related to this important structure. Finally, we included ROIs with multiple prior reports demonstrating a role in emotion regulation; however, we did not confirm that the changes in FC that we observed were associated with changes in emotion regulation beyond standardized depression scales.
Depression remains a major public health problem with current treatments taking weeks to months to induce remission, and there are millions of people who are not effectively treated with current methods.
Development of improved treatments could be accelerated by a better understanding of the neural changes that are necessary and sufficient to achieve disease remission. Our recent development of SAINT, which produces rapid and high rates of remission from MDD, provides an opportunity to begin searching for these neural changes. Our initial analysis of brain regions associated with emotion regulation demonstrates MDD remission is associated with a significant reduction in FC between sgACC and almost all major nodes of the DMN, bolstering prior hypotheses of the central role this network plays in MDD. We also found that decoupling of SN nodes was correlated with depression improvement, highlighting the role of other networks as well.
Overall our results reinforce the hypothesis that emotional dysregulation is a central mechanism of MDD and treating emotional dysregulation is an effective treatment strategy. As our current study is based on an open-label trial of SAINT, controlled trials will be necessary to determine which observed changes in FC are unique to SAINT and disease remission in order to prioritize network-level targets for further treatment optimization.
Materials and Methods
Participants
Detailed information regarding the participants, SAINT protocol, experimental design, and behavioral data analysis can be found in our prior report (19) . Briefly, 19 participants treated with SAINT had a diagnosis score higher than 20 and not have responded to at least 1 antidepressant medication (minimum trial duration of 6 weeks) to be eligible for the study. Participants had no history of a psychotic disorder, substance use disorder, major systemic illness, current mania (assessed using the Young Mania Rating Scale), lesional neurological disorder, or any contraindications to rTMS or MRI (such as implanted metal or history of seizures).
All participants provided written informed consent, and the study was approved by the Stanford University Institutional Review Board and in accordance to the Declaration of Helsinki.
Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT)
Participants received a 5-day treatment course under the SAINT protocol. Stimulation location was chosen based on an algorithm that selected the area within the left dorsolateral prefrontal cortex (lDLPFC) with the most negative FC with sgACC. This is described in detail in our prior report (19) . A MagVenture MagPro X100 (MagVenture A/S, Denmark) system was used to deliver sessions of intermittent theta-burst stimulation (iTBS): 60 cycles of 10 bursts of 3 pulses at 50Hz were delivered in 2 second trains (5Hz) with an 8 second inter-train interval. Stimulation sessions were delivered hourly. Ten sessions were applied per day (18,000 pulses/day) for 5 consecutive days (90,000 pulses in total). Stimulation was delivered at 90% resting motor threshold (rMT). A depth correction (95) was applied to the resting motor threshold to adjust for differences in the cortical depth of the individual's functional target compared to the primary motor cortex in order to consistently achieve 90% rMT in the intended functional target, but stimulation was never delivered above 120% rMT for safety. A Localite Neuronavigation System ( Localite GmbH, Sankt Augustin, Germany) was used to position the TMS coil over the individualized stimulation target. All participants in this report's subset completed the full 5-day treatment course.
Clinical assessment
Participants' depressive symptoms were assessed using the Hamilton Depression Rating Scale-17 item Head motion of participants was effectively minimized with the use of memory foam and inflatable padding.
Participant alertness during the resting state task was monitored using in-scanner video cameras.
The MRI data were preprocessed using FMRIPREPR version 1. 2.3 (97) [RRID:SCR_016216]. Each T1-weighted volume was corrected for intensity non-uniformity with N4BiasFieldCorrectionv2.1.0 (98) and skull-stripped using antsBrainExtraction.shv2.1.0 (using the OASIS template). Spatial normalization to the ICBM 152 Nonlinear Asymmetrical template version 2009c (99) [RRID:SCR_008796] was performed through nonlinear registration with the antsRegistration tool of ANTs v2.1.0 (100) [RRID:SCR_004757], using brain-extracted versions of both T1-weighted volume and template. Brain tissue segmentation of cerebrospinal fluid, white matter, and gray matter, was performed on the brain-extracted T1-weighted volume using fast (101) (FSL v5.0.9, RRID:SCR_002823).
The resting state data were motion corrected and then transformed into standard space (MNI).
Physiological noise regressors were extracted applying CompCor (102) . Framewise displacement (103) was calculated using the implementation of Nipype. Unsteady state volumes detected by FMRIPREPR were censored out (range 3 ~ 9, mean=5.12, SD=1.15). Independent component analysis-based Automatic Removal Of Motion Artifacts was used to non-aggressively denoise the data (104) . Next nuisance signal regression was applied with signals from white matter and cerebrospinal fluid. All the volumes with framewise displacement ( FD) greater than 0.2mm were excluded; this resulted in exclusion of 1 participant, as greater than half of the dataset had FD>0.2mm. All the data were spatially smoothed (6-mm-full-width, half-maximal Gaussian kernel) and temporal bandpass filtered (0.1-0.01 Hz). Data were detrended using Nilearn (105) .
Regions of interest (ROI)
For this initial analysis, we restricted our ROIs to brain regions that have consistently been reported to play a role in MDD and emotion regulation: DLPFC, VLPFC, DMN, sgACC, SN, insula, amygdala and striatum.
In line with prior studies (26, 37, (106) (107) (108) 
